7630 — IMPACT Therapeutics Income Statement
0.000.00%
Last trade - 00:00- HK$2.94bn
- HK$2.99bn
- CNY38.25m
Annual income statement for IMPACT Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 33.5 | 38.3 |
| Cost of Revenue | ||
| Gross Profit | 32 | 36.7 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Operating Interest Expense / Income | ||
| Unusual Expense / Income | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 233 | 266 |
| Operating Profit | -199 | -227 |
| Total Net Non Operating Interest Income / Expense | ||
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -255 | -296 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -255 | -296 |
| Net Income Before Extraordinary Items | ||
| Net Income | -255 | -296 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -255 | -296 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.921 | -1.03 |